UNJHAFOR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Unjha Formulations do?
Unjha Formulations Ltd is a leading manufacturer of pharmaceutical formulations including tablets, capsules, and injectables. They are renowned for producing and exporting Psyllium Husk & Powder in India.
Who are the competitors of Unjha Formulations?
Unjha Formulations major competitors are Shamrock Indl. Co, Colinz Laboratories, Beryl Drugs, Cian Healthcare, Decipher Labs, Parmax Pharma, Ortin Global. Market Cap of Unjha Formulations is ₹11 Crs. While the median market cap of its peers are ₹12 Crs.
Is Unjha Formulations financially stable compared to its competitors?
Unjha Formulations seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Unjha Formulations pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Unjha Formulations latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Unjha Formulations allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Unjha Formulations balance sheet?
Balance sheet of Unjha Formulations is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Unjha Formulations improving?
Yes, profit is increasing. The profit of Unjha Formulations is ₹1.02 Crs for TTM, ₹0.41 Crs for Mar 2025 and ₹0.28 Crs for Mar 2024.
Is the debt of Unjha Formulations increasing or decreasing?
The net debt of Unjha Formulations is decreasing. Latest net debt of Unjha Formulations is -₹1.6 Crs as of Sep-25. This is less than Mar-25 when it was -₹1.29 Crs.
Is Unjha Formulations stock expensive?
Unjha Formulations is not expensive. Latest PE of Unjha Formulations is 10.54, while 3 year average PE is 26.48. Also latest EV/EBITDA of Unjha Formulations is 7.54 while 3yr average is 25.45.
Has the share price of Unjha Formulations grown faster than its competition?
Unjha Formulations has given better returns compared to its competitors. Unjha Formulations has grown at ~27.25% over the last 4yrs while peers have grown at a median rate of -14.28%
Is the promoter bullish about Unjha Formulations?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Unjha Formulations is 36.92% and last quarter promoter holding is 36.92%.
Are mutual funds buying/selling Unjha Formulations?
There is Insufficient data to gauge this.
